Research
Energy balance
Semaglutide increases the proportion of people achieving 5% weight loss with a risk ratio of 2.68 (95% CI 2.30 to 3.12) at medium-term follow-up.
Semaglutide may significantly help adults with obesity achieve clinically relevant weight loss.
StrongSupportsmedium confidence
semaglutide increases the proportion of people achieving 5% weight loss (risk ratio (RR) 2.68, 95% CI 2.30 to 3.12; 12 studies, 7458 participants; high-certainty evidence).
Why this rating
Based on meta-analysis of randomized controlled trials.
Source
Semaglutide for adults living with obesity
Javier Bracchiglione et al. · Cochrane Database of Systematic Reviews · 2025
DOI 10.1002/14651858.cd015092.pub2
Meta-analysisCited 7×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Semaglutide reduces percentage body weight by a mean difference of -10.73 (95% CI -12.24 to -9.21) at medium-term follow-up.Strong
- Semaglutide likely results in little to no difference in quality of life with a mean difference of 2.12 (95% CI 0.95 to 3.28) in SF-36 physical functioning score at medium-term follow-up.Good
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →